To include your compound in the COVID-19 Resource Center, submit it here.

With GeneSight health economics data in hand, Myriad wins UnitedHealth coverage

Myriad Genetics jumped $15.87 (55%) to $45.01 Thursday, lifting its market cap by $1.2 billion to $3.3 billion, after UnitedHealth said it will begin covering its genetic depression test. The decision, which goes into effect Oct. 1,

Read the full 375 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers